 The disaccharide Galα1-3Galβ is the immunodominant saccharide in Leishmania cell surface and is the 32 unique non-reducing terminal glycosphingolipids structure recognized by anti-α-Gal.
difficult, requires technical skills, is prone to contamination, and is time-consuming. As all other parasitological method for Leishmania detection, the parasite culture does not allow Leishmania species determination. The 92 sensitivity of cultures depends on the parasite quantity, but is estimated to be between 60% and 85%. glycosylphosphatidylinositol (GPI) anchored to macromolecules such as metalloprotease and; 2) protein-free from cell death processes like lysis mediated by complement system, oxygen radicals and hydrolases in the 124 mammalian and insect host environments (ILGOUTZ et al., 2001; MUKHOPADHYAY et al., 2006;  produced can also represent a continuous immune response to Galα1-3 Gal structures found in various 134 gastrointestinal bacteria, confirming the polyreactive nature of these antibodies in human serum (GALILI, 1984;  135 GALILI et al., 1987; GALILI, 2013b) .
136
The major GIPLs found in these parasites' cell membranes include tetraglycosylinositol, 137 pentaglycosylinositol, and hexaglycosylphosphatidylinositol and sugar analysis of L. mexicana and L.
138
braziliensis GIPLs revealed monosaccharide composition of Manose (Man), Galactose (Gal), Glucosamine
139
(GlcN), and inositol (ÁVILA et al., 1991; MCCONVILLE & FERGUSON, 1993) .
140
Anti-α-Gal is the most abundant natural circulating human antibody and, since it binds specifically to 141 the Galα1-3Gal glycosphingolipids (GALILI, 1993; MARCHER et al., 2008; SCHOCKER et al., 2016) , it is 142 assumed that the majority of the anti-α-Gal binding sites expressed in the cell membranes of many organisms 143 have this non-reducing terminal structure (GALILI et al., 1988; GALILI, 1993; GALILI et al., 1995; GALILI, 2013a, b) . However, quantities of anti-α-Gal antibodies constantly produced can also represent a continuous immune response to Galα1-3 Gal structures found in various gastrointestinal bacteria (GALILI, 1984; GALILI 146 et al., 1987; GALILI, 2013b) , confirming the polyreactive nature of these antibodies in human serum 147 (SATAPATHY et al., 1999) .
148
The α-Gal has the potential for many clinical uses once anti-Gal antibodies are widely produced in 149 healthy humans and α-gal epitopes can be easily synthesized by several methods. This study describes an 
168
Individuals from H2 group were medically examined to discard any previous CL infection. CL 
175
Enzyme-linked immunosorbent assay (ELISA) 
177
To determine whether levels of anti-α-Gal antibodies in human serum, both non-infected and infected
178
with CL and other diseases can identify Leishmania α-Gal epitopes, optimal ELISA conditions were established, antigens (0.1 , 0.5 and 1 µg/well). Once the best condition was established, polystyrene microtiter plates with 96 wells (NUNC C96 Immuno Plate Maxisorp Surface, Thermo Scientific) were coated overnight at 4°C with 100 albumin serum, identified as NGP2203 -Dextra Laboratories) and one Galα1-3Gal analogue neoglycoprotein 185 with 3-atom spacer (Galα1-3Galβ1-3GlcNAc conjugated with human albumin serum, identified as NGP2333 -
186
Dextra Laboratories), diluted in carbonate-bicarbonate buffer (pH 9.6). In addition, the β-Gal NGP β1-4-
187
Galactosyl-Galactose conjugated with bovine serum albumin and with 3-atom spacer (NGP 0204, Dextra
188
Laboratories) was also included in the study as the "β-control" and soluble proteins from the crude extract from 
192
The following day, the plates were washed twice with 200 μL/well of washing solution (NaCl 0.9% +
193
Tween 20 at 0.05%), then the wells were blocked with 120 µL of blocking solution (Pierce Protein -Free T20 - 
197
Then the plates were washed four times with 200 μL/well of washing solution and polyclonal rabbit anti-human
198
IgG HRP conjugate (1.3 g/L, Dako) was diluted to 1:5,000 and was added to each well for one hour at 37°C. 
243
The presence of Leishmania anti-α-Gal antibodies was determined by comparing anti-α-Gal levels in 244 CL patients and healthy individuals living in the same endemic area, non-endemic area and individuals with 245 other diseases ( 
250
When comparing each sera group for each antigen singly (Table 4) , means of antibody titres of CL1
251
group from all NGPs showed no significant difference compared to the same group from L. braziliensis.
252
However, means of antibody titres of CL2 from NGP 2334 and CL3 groups from all NGPs showed higher 253 difference compared to the same groups L. braziliensis. Also, means of antibody titres of CL3 and CD groups 254 from NGP 0204 showed lower significant differences compared to all NGPs, indicating that the β-Gal NGP is 255 not able to be detected by antibodies of CD patients and/or CL patients after treatment.
257
Determination of α-Gal specific activity
259
To determine the specific immunogenic activity of the α-Gal residues, all NGPs, except for NGP 260 2204, were treated with α-galactosidase enzyme from green coffee beans, which specifically unlinks Galα1-261 3Gal into two parts -Galα1 and 3Gal -and, consequently, abrogates the recognition of α-Gal epitope by anti-α-
262
Gal antibodies (Figure 2 ). Although it is clear there is still an antigen-antibody reaction detected in the assay 263 performed with the presence of the α-galactosidase enzyme, compared to the controls, patients from the 264 CL1/CL2 and CL3 groups used in enzymatic treatment assay with NGP 2334 showed a 2-and 3-fold decrease 265 in the antibody titres than positive control, respectively. The same result was found for the other antigens: a 2.5-
266
and 4-fold decrease in the antibody titres for CL1/CL2 and CL3 groups for NGP 2333 antigen, respectively; and 267 2.5-and 4-fold for the CL1/CL2 and CL3 groups NGP 2203 antigen, respectively. H2 and H1 groups used in 268 enzymatic treatment also presented a decrease in the antibody titres when compared to the positive and negative 269 controls from non-enzymatic treatment.
DISCUSSION
Different NGP sequences were able to be better detected by anti-α-Gal antibodies from CL patients 273 under treatment and those that were under observation post-treatment compared to active CL patients, pointing 274 out that the increase in the anti-α-Gal levels could be used as a potential biomarker for detection the presence of 275 CL. However, means of antibody titres of CL patients with active lesions showed no difference compared to the 276 same group for positive control, meaning that all NGPs tested were able to detect anti-Leishmania antibody 277 levels in CL patients with active lesions at the same level of the crude extract from L. braziliensis. Previous 278 studies also suggest that sera from patients with active Leishmania lesions and cured individuals were able to 279 recognize α-Gal epitopes (ÁVILA et al., 1989; 1990; AL-SALEM et al., 2014) .
280
When Leishmania spread through the mammalian host cells, the parasites are rarely exposed directly 
287
No cross-reaction between the NGPs and antibodies from patients with other diseases was detected, 288 except for the Chagas disease, since the etiological agent of this disease is another trypanosomatid parasite.
289 Ashmus et al. (2013) also showed that chagasic anti-α-Gal antibodies strongly recognize saccharides containing 290 the non-reducing terminal disaccharide Galα1-3Galβ moiety.
291
The presence of different antibodies binding to similar epitopes, either in CL or patients with chronic
292
Trypanosoma infections can indicate the strong presence of highly immunogenic oligosaccharide antigens 293 linked to phosphatidylinositol in trypanosomatid parasites (ÁVILA et al., 1988; 1991) . Anti-α-Gal antibodies 294 specifically interact with glycoconjugates that have Galα1-3Galβ1-4GlcNAc residues but do not interact with
295
Galα1-4Galβ1-4GlcNAc, β-galactosyl, or glycoconjugates with other carbohydrate residues. The α-Gal binding 296 site has a size corresponding to the free trisaccharide Galα1-3Galβ1-4GlcNAcα-and it exhibits seven-fold 297 higher in affinity of human anti-α-Gal than that to the disaccharide Galα1-3Gal, and much more strongly than α-
298
Gal alone (GALILI et al., 1985; GALILI, 1989; 2013b; OBUKHOVA et al., 2007; SCHOCKER et al., 2016) . A 299 decrease of antibody titres from CL patients was noticed when the α-Gal residues specific immunogenic activity protocol was applied. The same results were observed by Galili et al. (1984) and Ávila et al. (1988; 1989; 1990; conclusion that the disaccharide Galα1-3Galβ is the immunodominant saccharide in Leishmania cell surface and 303 is the unique non-reducing terminal glycosphingolipids structure recognized by anti-α-Gal. Table 1 . Demographic data of the study cohort. H1: healthy individuals from non-endemic areas, H2: healthy the subsequent 3 months, OD: serum reagent patients for other diseases such as Hepatitis B and C, Syphilis
481
(diagnosis performed by a blood bank) and truly positive patients for Tuberculosis , CD: serum reagent patients 482 for Chagas disease (diagnosis performed by a blood bank).
P16
Skin lesion and positive intradermal reaction Hadn't started the treatment yet 
545
disease and other diseases, performed using R software with auxiliary pROC system. NGP 2334: Galα1-areas, CL1: CL patients with active lesions and no treatment, CL2: CL patients with active lesions under the 560 treatment, CL3: CL patients that had finished treatment and were under observation for the subsequent 3
